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SUMMARY – Rituximab is a chimeric monoclonal CD20 antibody used in the treatment of 
CD20 positive non-Hodgkin lymphomas and has revolutionized treatment approach to these hema-
tologic malignancies in the last decade. Th e main aim of this review is to present data on the use of 
rituximab in the treatment of follicular lymphoma (FL). We will focus on rituximab maintenance 
strategies in the fi rst and second line treatment. Th is approach has improved the outcome in FL pa-
tients with better progression-free survival in all patients and better overall survival in relapsed setting. 
Regardless of good results, this strategy has generated controversies in medical community in the 
range from the lack of overall survival benefi t in fi rst line setting, adverse eff ects of possible overtreat-
ment and toxicities to its unknown role in the era of novel agents. Th e existing data suggest that 
rituximab maintenance should be a rational therapeutic option for all patients with FL responding to 
fi rst line therapy and transplant-ineligible patients responding to reinduction.
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Introduction
Follicular lymphoma (FL) is one of the most com-
mon subtypes of non-Hodgkin lymphoma (NHL). A 
recent survey in the United States that included 
596,476 patients with newly diagnosed NHL over a 
period of 14 years demonstrated that FL was the sec-
ond most common subtype of NHL, accounting for 
17.1% of cases1,2. In Croatia, the incidence of NHL is 
5.57 per 100,000 of men or women, as reported by No-
vak et al. for the 2005-2009 period3. FL accounts for 
20.2% of NHL cases in Croatia as demonstrated re-
cently by the international NHL classifi cation proj-
ect4. Th e histology of FL is characterized by germinal 
centers of B lymphocytes, predominantly centrocytes 
and centroblasts with follicular growth pattern2,5. Th ey 
harbor universal translocation t(14;18)(q32;q21) in-
volving the rearrangement of BCL2 and IgH in most 
cases. Morphologically, four diff erent grades are recog-
nized, based on the number or centroblasts per high 
power fi eld with FL grade 4b being a distinct entity 
due to diff erent biological and clinical behavior2,6. It is 
also characterized by expression of BCL2, BCL6, 
CD20, CD19 and monoclonal immunoglobulin light 
chain.
Th e course of the disease is marked by indolent 
course, frequent relapses, ‘incurability’, and tendency 
to transform into more aggressive NHL (diff use large 
B cell lymphoma). It is important to note that not all 
patients are treated initially due to the ‘watch and wait’ 
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strategy. Th e most commonly used treatment criteria 
(GELF) are presented in Table 17. Controversies re-
main regarding treatment rationale in cases of low tu-
mor mass8,9. Furthermore, newly diagnosed FL pa-
tients should be stratifi ed according to FLIPI-1 or 
FLIPI-2 criteria (Table 2) in order to predict the out-
comes and overall survival (OS)10,11.
Th e main aim of this review is to analyze the exist-
ing data on the current treatment of FL with special 
emphasis on maintenance therapy.
Historical Overview of Advances 
in Follicular Lymphoma Th erapy
Prognosis in patients diagnosed with FL was poor. 
In a retrospective single-center analysis from the 
1970s, the 5-year OS was 54%, deteriorating to 34% in 
patients older than 5012. Disease-free survival after 
5-year follow up was only 18% of patients. However, 
these numbers improved as outlined by the recent EU-
ROCARE 5 report13. A subanalysis for hematologic 
malignancies was performed for 1997-2007 including 
32,110 FL cases14. Considerable improvement was re-
corded in 5-year OS of FL patients and in comparison 
to other lymphoid malignancies, rising from 58.9% in 
the 1997-1999 period to 74.3% in the 2006-2008 pe-
riod. Th ere are several reasons for this improvement in 
outcomes, but for the purpose of this review we will 
state only two, i.e. the widespread introduction of 
rituximab, a chimeric antiCD20 antibody, and im-
provement in autologous stem cell transplantation 
(ASCT).
In the report of the European Society for Blood 
and Marrow Transplantation (EBMT) study, which 
included 693 patients followed-up for at least 15 years, 
the outcomes of ASCT for FL are presented15. Th e 
median progression-free survival (PFS) at 5, 10 and 15 
years was 41%, 28% and 26%, respectively, with a pla-
teau in the survival curve indicating satisfactory dis-
ease control in one-quarter of patients with relapsed or 
refractory FL. Th e median OS for ASCT at 5, 10 and 
15 years was 64%, 52% and 47%, respectively. In a 
study of 121 patients undergoing ASCT at second re-
mission or subsequent relapse, followed-up for at least 
12 years, PFS was 55% at 5 year and 48% at 10 years16. 
Th ese results also show adequate tumor control, which 
can be obtained by ASCT. Th e only factor associated 
with longer OS was ASCT at 2nd complete remission 
(CR). Th is treatment approach was also embraced of-
fi cially by the leading international guidelines and sub-
sequently by the Croatian Society of Hematology and 
Transfusion in the national lymphoma guidelines17-19.
Another important improvement in the treatment 
of FL patients was the introduction of rituximab. Th e 
pivotal study included 166 patients with relapsed FL 
or other low grade NHL on infusion regimen with 
375 mg/m2 once weekly for 4 weeks20. Th e overall re-
sponse rate (ORR) was 48% and PFS 13 months. Tox-
icities were mild and the effi  cacy was comparable to 
the cyclophosphamide, doxorubicin, vincristine and 
prednisone (CHOP) chemotherapy regimen, then 
considered as the gold standard for indolent lympho-
mas. Th is study led to approval of rituximab for re-
lapsed indolent NHL in 199721. With its impressive 
activity and low toxicity profi le, the question arose if 
rituximab could be further combined with conven-
tional chemotherapy to improve outcomes in these 
patients. Preliminary data on preclinical models sup-
Table 1. GELF proposal as a reason to start treatment7
Reason to start treatment
Involvement of 3 nodal sites (diameter ≥3cm)
Any tumor mass greater than 7 cm
B symptoms
Pleural eff usion or ascites
Cytopenia (leukopenia, thrombocytopenia)
Leukemia (≥5x109 of malignant cells)




Age ≥60 years Beta 2 microglobulin 
≥ULN
Ann Arbor stage III or IV Bone marrow involvement
Hemoglobin ≤120 g/L Age >60 years
Serum LDH ≥ULN Hemoglobin ≤120 g/L
Number of nodal sites ≥5 Longest nodal diameter 
>6 cm
*number of factors: 0-1 low risk group; 2 intermediate risk group; 3 
or more high risk group; **number of factors: 0 low risk group; 1-2 
intermediate risk group; 3 or more high risk group; ULN = upper 
normal limit; LDH = lactate dehydrogenase
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ported in vivo synergistic eff ects of rituximab with cy-
totoxic drugs22. However, it took years to translate 
these fi ndings into clinical reality. Th e fi rst pivotal ran-
domized trial published in 2005 compared cyclophos-
phamide, vincristine and prednisone (CVP) with 
rituximab-CVP (R-CVP)23. It included 321 patients 
with stage III or IV FL. Primary objective was time to 
treatment failure (TTTF). TTTF was signifi cantly 
longer in R-CVP group as compared with CVP group 
(27 months vs. 7 months). ORR rates were 81% and 
57%, respectively, indicating superior tumor control in 
rituximab group with prolonged duration of response 
(35 months vs. 14 months). Concerning toxicity pro-
fi le, the addition of rituximab resulted in infusion reac-
tions that were manageable and higher rates of neutro-
penia but without any clinical repercussion. Th e au-
thors conclude that R-CVP represents a novel, im-
proved standard of care in FL, which was recognized 
by regulatory agencies24. Th e results of this study were 
updated with a longer follow up of 53 months showing 
the superiority of R-CVP with OS benefi t (83% vs. 
77%)25. Subsequently, additional improvements of the 
fi rst line rituximab-containing regimen were explored. 
Rituximab was also included in the anthracycline-
based CHOP regimen in a trial including 428 high 
tumor burden FL patients26. Better ORRs, longer time 
to treatment failure (60% TTTF reduction) and dura-
tion of response, and better 2-year OS rates (95% vs. 
90%) were achieved with R-CHOP as compared to 
CHOP. Th is study added to the on-going heated dis-
cussion whether to use anthracyclines in the frontline 
therapy for better tumor control in FL. A meta-analy-
sis that included four clinical trials was performed to 
answer this review question27. Th erapy with R-CVP 
enabled higher CRs while R-CHOP was associated 
with better ORRs. However, the pitfall of this system-
atic review was not analyzing long term FL outcomes, 
and the authors conclude that the choice of the regi-
men should be decided individually based on the need 
to avoid anthracycline cardiotoxicity in older patients 
or in young patients where salvage therapy followed by 
ASCT is planned in the future. A recent Cochrane 
meta-analysis including 8 randomized control trials 
investigated the eff ect of adding anthracycline in treat-
ing FL on long term outcomes28. No OS benefi t was 
recorded while PFS was in favor of anthracycline us-
age. However, anthracycline was associated with high-
er toxicity, primary cytopenias and cardiotoxicity, 
which limit its application. Th e use of R-CHOP or 
R-CVP currently depends on the experts’ judgment 
until the large observational trials such as RE-
FLECT-1 provide answer to this question29.
First line therapy including rituximab has achieved 
excellent tumor control and reduction, but the ques-
tion remains if additional benefi t of rituximab may be 
exploited to reduce relapses and prolong PFS without 
the need for further cytotoxic treatment.
Th e Rationale for Rituximab 
as Maintenance Th erapy
After encouraging results of the pivotal study on 
rituximab, additional analysis was conducted based on 
the pharmacokinetics and response20,30. Overall, ritux-
imab serum concentrations increased and accumulated 
after each infusion with slow clearance during post 
treatment follow up. Additionally, the authors found 
that serum concentration of rituximab was signifi cant-
ly higher in responders when compared to non-re-
sponders, especially during follow up. Additional pa-
rameters associated with elevated rituximab concen-
tration were B-cell depletion, reduction of the largest 
tumor diameter, and the sum of diameter of six largest 
tumor lesions. Th e authors conclude that this may rep-
resent additional antitumor activity of rituximab and 
that higher concentrations may have a benefi cial clini-
cal eff ect. Th ese fi ndings were further clinically con-
fi rmed in a randomized control trial by Ghielmini et 
al.31. In 185 treatment naïve or relapsed FL patients, 
rituximab was administered once weekly for four 
weeks. After induction, they were randomized to re-
ceive additional four doses of rituximab every 8 weeks 
(‘prolonged phase’) or had no additional therapy. Pri-
mary outcome of the study was EFS which was sig-
nifi cantly longer in ‘prolonged’ group (23.2 months vs. 
11.8 months). Overall, the risk of disease related event 
decreased by 60%. Th e prolonged treatment was not 
associated with any clinically relevant toxicity. In con-
clusion, prolonged rituximab exposure is associated 
with benefi cial eff ects in FL with more favorable out-
comes. Th is trial provided evidence to further explore 
if rituximab could be used as maintenance therapy for 
reducing the relapse rates and the need for additional 
chemotherapy.
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Maintenance with Rituximab 
in Relapsed Follicular Lymphoma
Th e fi rst randomized phase III trial explored ritux-
imab maintenance in 176 patients with relapsed or re-
fractory FL or mantle cell lymphoma32. Reinduction 
was induced with fl udarabine, cyclophosphamide and 
mitoxantrone (FCM) with or without rituximab. Ow-
ing to the more favorable ORRs in R-FCM group, 
fi rst randomization was stopped and additionally re-
cruited patients were allocated to R-FCM group. Sec-
ond randomization of responding patients involved 
rituximab maintenance (2 courses of 4-times-weekly 
doses at 3rd and 9th month) and observation. Primary 
objective of the study was response duration, which 
was not reached in maintenance group vs. 17 months 
in observation group after median follow up of 26 
months. When analyzing for the subtypes of NHLs, 
diff erence persisted in FL patients. Regarding toxicity, 
only one discontinuation occurred due to severe infu-
sion reactions, but lymphocytopenia was most pro-
nounced without infections.
A rituximab maintenance study in relapsed and re-
fractory FL patients was carried out by EORTC 
group, involving 456 patients randomized at 1:1 ratio 
to receive either R-CHOP or CHOP as reinduction 
therapy33. Second randomization included rituximab 
maintenance administered once in 3 months for 2 
years or observation. As expected, the addition of 
rituximab to CHOP regimen resulted in better ORRs 
and PFS. Promising disease control, defi ned as PFS of 
51.5 months was achieved as compared to only 14.9 
months in observation arm for the whole group. PFS 
remained signifi cant when adjusting for R-CHOP or 
CHOP regimens, for the fi rst time showing that 
maintenance strategy following the standard of care 
improved outcomes in these patients. Furthermore, 
PFS translated in OS benefi t with 3-year OS rate was 
85.1% in maintenance group as compared with 77.1% 
in observation group. Additional safety risks arose in 
patients in the maintenance group being more prone 
to neutropenia (10.8%) and infections (9%). Th is tox-
icity was manageable and no death related to treat-
ment was recorded. EORTC trial has demonstrated 
major improvements in care for relapsed or refractory 
FL patients, leading to approval of rituximab mainte-
nance for this indication20. Long term follow up (me-
dian 6 years) of the trial was published, again demon-
strating better PFS in maintenance group as compared 
to observation group (3.7 years vs. 1.7 years)34. How-
ever, the benefi t in OS was lost probably due to the 
bias produced by consequent retreatment regimens 
containing rituximab. Subsequent meta-analysis in-
cluded 6 randomized controlled trials including 909 
patients with relapsed or refractory FL35. Improved 
OS was seen in maintenance group with hazard-ratio 
of death estimated to 0.72. Th erefore, current evidence 
shows not only PFS, but also OS benefi t in this sub-
group of patients (Table 3). Accordingly, the Croatian 
national guidelines for lymphoma diagnostics and 
management have included rituximab maintenance in 
second CR or partial remission in transplant ineligible 
patients19.
Rituximab Maintenance as Part of First Line 
Th erapy of Follicular Lymphoma
Preliminary results of rituximab maintenance ther-
apy after rituximab induction at four weekly doses 
Table 3. Summary of selected phase III randomized control trials on maintenance therapy in relapsed or refractory 
follicular lymphoma
Study N Reinduction Primary objective Overall survival
Forstpointner et al.32* 176 R-FCM Response duration: median 
not reached vs. 17 months
77% vs. 57%****
van Oers et al.33** 456 R-CHOP
CHOP
PFS: 51.5 months vs. 14.9 months 85.1% vs. 77.1%
van Oers et al.34*** 456 R-CHOP
CHOP
PFS: 3.7 years vs. 1.7 years 74.3% vs. 64.7%****
*follow up 26 months, 3-year OS rate; **follow up 33.3 months, 3-year OS rate; ***follow up 6 years, 5-year OS rate; ****nonsignifi cant; OS 
= overall survival; R-FCM = rituximab, fl udarabine, mitoxantrone, cyclophosphamide; R-CHOP = rituximab, cyclophosphamide, 
doxorubicin, vincristine, prednisone; CHOP = cyclophosphamide, doxorubicin, vincristine, prednisone
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showed improved PFS, as described previosly31. An-
other study explored this strategy in rituximab-naïve 
patients36. Th e study enrolled 387 patients suff ering 
from indolent NHL, most of them FL. Th e induction 
regimen was CVP. Patients were then randomized ei-
ther to maintenance therapy (four doses of rituximab 
monthly at 6-month intervals, 4 courses) or observa-
tion arm. Th ree-year PFS was 68% in maintenance 
group versus 33% in observation group. PFS advantage 
did not signifi cantly translate into OS rates. More im-
portantly, the study has reported conversion to better 
response to CVP during rituximab phase in 22% of 
patients compared with only 7% in observation group, 
indicating that not only rituximab maintenance im-
proved outcomes in terms of PFS, but could addition-
ally improve ORRs to prior induction regimen. No 
data on toxicity were provided in the study. Th ese stud-
ies used historical regimens (CVP, rituximab 4 doses 
weekly) and the need arose to explore maintenance 
strategy in contemporary setting. In one of the largest 
trials to date, PRIMA, which enrolled 1217 patients 
suff ering from untreated high burden FL, newer treat-
ment regimens were used37. All patients were treated 
with one of the following chemotherapy regimens: R-
CHOP, R-CVP or R-FCM. After the end of treat-
ment, 1019 patients were randomized into rituximab 
maintenance group (rituximab therapy once in two 
months for two years) or observation group. Primary 
endpoint was PFS. Th e 3-year PFS rate was 74.9% in 
rituximab group as compared with 57.6% in observa-
tion group, with median follow up of 36 months. Fur-
thermore, as shown by previous study, this strategy 
may contribute to conversion to optimal response, i.e. 
72 patients with PR were converted to CR during the 
maintenance phase. Once again, PFS did not translate 
into OS benefi t. Results with a longer follow up (me-
dian 6 years) have been reported38. Th e 6-year PFS rate 
was 59.2% for maintenance group versus 42.7% in ob-
servation group. Time to next lymphoma treatment or 
chemotherapy was signifi cantly longer in the mainte-
nance group. Th e maintenance strategy did not aff ect 
second line treatment of FL with CRs being similar 
between the groups. However, no signifi cant diff erence 
in OS has been reported. Based on the results of PRI-
MA trial, rituximab was approved by regulatory agen-
cies for another indication as fi rst line maintenance 
therapy in previously untreated FL responding to in-
duction therapy24.
It should be stressed that one study did not fi nd 
benefi t of maintenance therapy in FL. Th is trial was 
conducted in elderly, untreated patients (N=234) using 
rituximab, fl udarabine, mitoxantrone and dexametha-
sone (R-FND). Patients were randomized in ritux-
imab maintenance (one dose every four months, total 
of four doses) or observation arm. Primary endpoint of 
the study was 2-year PFS reaching 81% in rituximab 
group versus 69% in maintenance group. However, this 
diff erence was not statistically signifi cant (p=0.226)39. 
Th ere may have been several reasons, e.g., short follow 
up, limited rituximab exposure, small sample under-
powered to detect diff erence and use of non-standard 
immunochemotherapy regimen in the fi rst line setting. 
An updated meta-analysis has consistently shown im-
provement in PFS across various studies (N=5), but 
again without translation in OS35. Data on rituximab 
in fi rst line maintenance therapy treatment of FL are 
summarized in Table 4.
Controversies Surrounding Maintenance Th erapy 
in Advanced High Burden Follicular Lymphoma: 
to Maintain or not to Maintain?
So far, we have described relevant clinical trials of 
maintenance strategy in FL and several controversies 
have arisen. Th is will be discussed regarding routine 
clinical practice.
Th e role of autologous stem cell transplantation 
for relapsed follicular lymphoma in rituximab era
One of the few clinical trials examining ASCT and 
conventional therapy (N=89) showed OS and PFS 
benefi t, but was performed before the advent of ritux-
imab40. Th e largest data set on ASCT comes from 
various retrospective series (e.g., EBMT), while data 
on ASCT during rituximab availability are scarce15,41. 
In a retrospective analysis by the French GELA group, 
254 patients with relapsed FL were included42. Pa-
tients treated with rituximab-based regimen had sig-
nifi cantly better outcomes (OS and EFS) than those 
treated with ASCT, but adding rituximab to salvage 
regimen followed by ASCT resulted in the most effi  -
cient disease control (OS and EFS not reached). Ac-
cording to the Croatian national guidelines, salvage 
chemotherapy containing rituximab followed by 
ASCT is recommended for young, fi t patients without 
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signifi cant comorbidities19. Th e issue of possible omis-
sion of ASCT in FL must be resolved in the context of 
randomized clinical trial examining ASCT compared 
to rituximab maintenance approach. To our knowl-
edge, no such trial has been performed. As stated pre-
viously, in transplant non-eligible patients, rituximab 
post-reinduction maintenance approach is a standard 
of care since benefi ts are recorded in both PFS and 
OS17,18,35.
Is progression-free survival a valid endpoint 
in follicular lymphoma?
One of the main criticisms of rituximab mainte-
nance therapy in high tumor burden FL is the fact that 
improvement in PFS has not yet translated in OS ben-
efi t by clinical trials and meta-analyses31,35-39,43. Several 
factors aff ecting OS in FL should be taken into ac-
count. First, FL is characterized by an indolent course 
leading to high OS rates and front-line rituximab con-
tributed to 74.3% of 5-year OS rate1,14. A follow up 
longer than 5 years would provide information if PFS 
will translate in OS. Second, for relapsed patients the 
established second line rituximab regimens and ASCT 
may result in additional OS interpretation bias due to 
long term remissions, which directly infl uences the OS 
curve. In a recent review by Korn and Crowley, PFS 
was highlighted as a powerful endpoint in clinical tri-
als to be included in future studies44. In the time of 
accelerated approvals of cancer drugs on the basis of 
surrogate endpoints such as response rates with suffi  -
cient duration (i.e. pathologic complete response to 
neoadjuvant therapy in breast cancer) or molecular re-
missions (e.g., tyrosine kinase inhibitors for chronic 
myelogenous leukemia), evidence for clear PFS benefi t 
by rituximab maintenance in FL might be considered 
suffi  cient ground for inclusion in routine protocols45.
To retreat or to maintain?
Rituximab has been established as maintenance 
therapy, but its possible role in retreatment was also 
assessed. Th e fi rst phase II randomized controlled trial 
included 114 rituximab naïve and previously relapsed 
patients with indolent NHLs46. Subjects fi rst received 
4 weekly rituximab infusions followed by maintenance 
(four courses of 4 doses of rituximab every 6 months) 
or reinduction with rituximab after disease progres-
sion. Primary objective was duration of rituximab 
 benefi t, which was 31.3 months in maintenance 
group versus 27.4 months in observation group. 
 However, although the diff erence in primary outcome 
was not statistically signifi cant, PFS was signifi cantly 
longer in the maintenance group (31.7 vs. 7.4 months) 
with a higher rate of CRs and continuous remissions. 
When analyzing the results, we must take in account 
that this trial was designed in the era when rituxi-
mab was only approved for relapsed FL. Further bias 
when interpreting the results may be due to short 
 follow up and unbalanced numbers across the groups 
Table 4. Data from selected phase III randomized controlled trials on rituximab maintenance following fi rst line 
therapy in high burden follicular lymphoma
Study N Induction Primary objective Overall survival
Ghielmini et al.31* 64 Rx4 EFS: 36 vs. 19 months Not reported
Hochster et al.36** 288 CVP PFS: 68 vs. 33 months 92% vs. 86%******
Salles et al.37*** 1217 R-CVP
R-CHOP
R-FCM
PFS:74.9 vs. 57.6% months No signifi cant reduction in hazard 
ratio for death
Salles et al.38**** 1217 R-CVP
R-CHOP
R-FCM
PFS: 59.2 vs. 42.7% 84.7% vs. 88.7*****
Vitolo et al.39***** 234 R-FND PFS: 81% vs. 69% ****** Not reported for groups
*median follow up 35 months; **median follow up 3.7 years, 3-year survival rates; ****median follow up 3 years, 3-year survival rates; 
*****median follow up 6 years, 6-year survival rates; ******median follow up 2 years, 3-year survival rates; ******nonsignifi cant; R = rituximab; 
CVP = cyclophosphamide, vincristine, prednisone; CHOP = cyclophosphamide, doxorubicin, vincristine, prednisone; FCM = fl udarabine, 
mitoxantrone, cyclophosphamide; FND = fl udarabine, mitoxantrone, dexamethasone; EFS = event-free survival; PFS = progression-free 
survival
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due to early progressions prior to starting maintenance 
therapy.
Th e groundbreaking trial was the RESORT trial 
including 289 treatment naïve low burden FL pa-
tients47. After 4 weeks of rituximab induction, the sub-
jects were randomized to either receive single ritux-
imab infusion every 13 weeks (maintenance group) or 
reinduction in case of progression (retreatment group). 
Th e study had two primary objectives, i.e. TTTF and 
time to fi rst cytotoxic therapy. TTTF did not statisti-
cally diff er between the groups being 3.9 years in re-
treatment group versus 4.3 years in maintenance group. 
Time to fi rst cytotoxic therapy was signifi cantly longer 
in maintenance group as compared to retreatment 
group. Th e authors concluded that the retreat scheme 
was as effi  cacious as maintenance strategy, therefore 
reducing overtreatment in this group. Th e results of 
this study were greeted with great enthusiasm by 
maintenance opponents as the ‘fi nal nail in mainte-
nance coffi  n’48,49,53. Still, great care should be exercised 
regarding extrapolation of these results to treatment of 
advanced FL. Considering the relatively short EFS of 
11.8 months in fi rst line rituximab induction therapy 
without extended use, retreatment strategy may not be 
as eff ective in high tumor burden FL, but this pre-
sumption was not analyzed. Although the retreatment 
option with rituximab may be attractive due to the ac-
ceptable toxicity profi le and probable cost-eff ective 
benefi t, in the absence of data for advanced FL, stan-
dard maintenance therapy should represent good clin-
ical practice.
Toxicity of rituximab maintenance
Concerning the safety profi le of rituximab mainte-
nance, the largest set of data comes from the PRIMA 
trial37. Th e frequency of adverse events equal and 
greater than 3 occurred in 24% of patients in mainte-
nance group as compared to 17% events in observation 
group. Th e most common events were new malignancy 
(4%), neutropenia (4%) and infections (4%). Discon-
tinuation rate due to adverse events was 4% in mainte-
nance group. Continuous rituximab exposure can 
cause low plasma immunoglobulins, but no signifi cant 
decrease in immunoglubulins A, M and G was found 
in either group. Also, the incidence of transformation 
to aggressive diff use large B cell lymphoma did not 
diff er between the groups and no other safety risks 
were observed38. Safety of rituximab maintenance 
treatment was investigated in MAXIMA, a phase IIIb 
trial, including 545 patients with previously untreated 
or relapsed FL50. Hematologic adverse events equal 
and greater than 3 occurred in 4.4% of subjects with 
the most prominent event being neutropenia (2.4%), 
but only 4 cases of febrile neutropenia were recorded. 
Concerning infections, 4.3% of events equal or greater 
than 3 were recorded, with pneumonia as the most fre-
quent one. Infections of grade 1 or 2 were more com-
mon, including nasopharyngitis (7.1%), bronchitis 
(4.7%) and sinusitis (4.3%). Grade 3 or 4 hypoimmu-
noglobulinemia developed in 4 patients, and in 32 pa-
tients hypoimmunoglobulinemia was of prolonged 
duration, but this event was self-limiting and did not 
require intervention in most cases.
In a systematic review of rituximab maintenance 
therapy that included 11 clinical trials and 1009 pa-
tients suff ering from FL or MCL, suppression of bone 
marrow and infections were most common toxicities, 
with 24% of patients experiencing grade 3 or 4 toxici-
ty51. Signifi cantly less toxicity was found in the regi-
men of 4 weekly rituximab infusions every 6 months 
compared to PRIMA schedule (once in two months 
for 2 years), i.e. 12% and 35%, respectively. Th e system-
atic review also included MCL patients, which prob-
ably aff ected the results, as MCL patients are treated 
with more aggressive therapy in fi rst line treatment 
(high doses of cytarabine with cumulative toxicity). 
Rituximab maintenance therapy is associated with few 
side eff ects, which are tolerable and mostly do not 
cause discontinuation. While PRIMA schedule should 
remain the standard of care, in specifi c patient popula-
tions (elderly, unfi t, and those prone to infectious com-
plications) alternative approach with rituximab (four 
weekly doses every 6 months for four cycles) may be a 
sound option.
Rituximab maintenance therapy and quality of life
Th e World Health Organization defi nes the qual-
ity of life (QoL) as the “individuals’ perception of their 
position in life in the context of the culture and value 
systems in which they live and in relation to their 
goals, expectations, standards and concerns”53. QoL as 
an important medical issue has substantial impact on 
designing of clinical trials, mostly as self-reported sec-
ondary endpoint. Two diff erent QoL questionnaires 
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were applied in PRIMA trial and no diff erence was 
found between maintenance and observation group37. 
Th is has led to criticism that QoL is not improved in 
these patients, thus failing in secondary endpoint43. 
Th is is apparently confl icting, but the treatment did 
not further deteriorate QoL. Also, patients were cen-
sored at the time of progression, so prospective data on 
the possible deterioration in QoL during relapse and 
the true impact of maintenance strategy on QoL will 
remain unknown. It is important to note that relapsed 
FL patients experience a rapid decline in QoL, as 
demonstrated in a series of 222 patients during diff er-
ent disease states, but in relapsed setting53. Th e im-
provement in QoL as a valid surrogate outcome of 
treatment was recently raised by a prospective clinical 
trial including 379 asymptomatic, low tumor burden 
FL patients9. Th e main question of the trial was com-
parison of outcomes between the ‘watch and wait’ 
strategy versus rituximab treatment. By randomizing 
patients into three groups (‘watch and wait’, rituximab 
induction, and rituximab maintenance), the authors 
showed the expected improvement in time to next 
therapy in rituximab groups. Interestingly, the second 
main endpoint was improvement in QoL. Th e active 
approach, i.e. rituximab maintenance, signifi cantly im-
proved QoL in these patients, indicating that active 
approach towards illness improves many lifestyle as-
pects, including coping mechanisms and emotional 
status. QoL as primary endpoint has its drawbacks due 
to the existence of various, more cost-eff ective inter-
ventions in this group such as psychotherapy54. In con-
clusion, it is hard to extrapolate the fi ndings of these 
studies, whether maintenance therapy improves QoL 
of FL patients indeed, but it is important to note that 
this strategy does not have negative impact, thus sug-
gesting another argument for the validity of this ap-
proach.
Th e cost-eff ectiveness of rituximab maintenance
Th e cost of rituximab maintenance strategy is an 
important issue43. In a recent retrospective health eco-
nomics US study that included 1002 patients with FL 
from MEDICARE database, the cumulative one-year 
cost for patients that progressed was 30,890 USD 
(N=268) versus only 8704 USD for those in observa-
tion group (N=734)55. Th e outpatients, inpatients, che-
motherapy and acute care visits were more frequent in 
progression group associated with higher cost of care 
and its impact on healthcare system. Th is study indi-
rectly provides the rationale that the prolongation of 
PFS in FL patients is associated with lower healthcare 
burden and costs, and provides evidence that mainte-
nance therapy can indeed be cost-eff ective. One of 
earlier cost-eff ectiveness studies of rituximab mainte-
nance comes from the Swedish group56. Th ey based 
their fi nancial model on the phase III trial in relapsed 
setting conducted by EORTC group33. Incremental 
cost per quality-adjusted life-years (QALY) was esti-
mated to 12,600 € for rituximab group, while the cost 
per life-years-gained (LYG) was 11,200 €. In all of the 
simulations, rituximab maintenance was associated 
with incremental costs which were less than 25,400 €. 
With regard to willingness-to-pay value in Sweden of 
up to 54,000 € per intervention, rituximab mainte-
nance in relapsed setting was cost-eff ective. Recently, a 
Dutch population-based study used registry data com-
prising 3581 patients with relapsed FL undergoing 
maintenance therapy57. Th e incremental cost-eff ective-
ness ratio (ICER) was 11,254 € per QALY and 10,591 
€ per LYG. ICERs slightly diff ered in two studies 
(EORTC trial and matched-real world scenarios), but 
in conclusion rituximab maintenance in relapsed pa-
tients was found to be cost-eff ective and in line with 
Dutch healthcare policy makers. Similar results were 
obtained by a French economic analysis based on 
EORTC trial estimating ICER of 7612 € per LYG 
and 8729 € per QALY33,58. Th ese data demonstrate that 
rituximab maintenance is cost-eff ective in relapsed FL 
setting and its ICER is well below willingness-to-pay 
value for oncologic drug.
Th e earliest data on rituximab maintenance cost-
eff ectiveness in fi rst line setting come from US group 
based on the results of PRIMA trial37,59. Total cost of 
maintenance therapy was estimated to be 38,545 USD 
with ICERs being 31,394 and 34,842 USD for LYG 
and QALY, respectively. Th e majority of US studies 
use ICER per QALY threshold as 50,000 USD, this 
approach seems to be cost-eff ective from US point of 
view60. In Europe, only one health economics study 
from the UK National Institute for Health and Care 
Excellence examined rituximab maintenance61. Most 
of ICERs per QALY were under 30,000 GBP, as re-
ported by the manufacturer, while Evidence Review 
Group estimated ICERs per QALY to range between 
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24,600 and 35,000 GBP based on the scenario. Th e 
review group has concluded that rituximab mainte-
nance is cost eff ective for the National Health System 
resources, which evaluate ICER per QALY as 30,000 
GBP. Data were from primary PRIMA study with a 
short follow up, which possibly infl uenced the results. 
Future studies including real-world data are needed to 
address this issue.
Rituximab maintenance at the dawn of new drugs 
for indolent non-Hodgkin lymphoma: still necessary?
Th e past several years have certainly been exciting 
for indolent NHLs, particularly FL with the introduc-
tion of new drugs possibly changing treatment op-
tions. Th e fi rst drug of interest is certainly bendamus-
tine (B), an ‘old’, but new drug in the fi eld. Bendamus-
tine acts as a potent alkylating agent, indeed more 
potent than cyclophosphamide62, which also is not 
cross-resistant with other members from the group. 
Th e activity of bendamustine was demonstrated in 
early clinical trials in refractory or relapsed indolent 
NHLs resulting in high ORRs and durable remissions 
as a single agent or in combination therapy resulting in 
FDA approval for rituximab-resistant indolent 
NHLs63. However, the true value of bendamustine was 
recognized in fi rst line therapy of iNHLs. First ran-
domized clinical trial compared bendamustine in 
combination with rituximab (R-B) to standard R-
CHOP therapy in indolent and mantle cell lympho-
mas64. Th is combination resulted in improved PFS 
when compared to standard arm across all NHLs his-
tology. Also, its toxicity was more tolerable with fewer 
hematologic and other adverse events (mostly infec-
tions). Th e results of this trial produced the hype that 
the era of R-CHOP had ended65. However, despite 
the non-inferiority design, BRIGHT study compared 
R-B to R-CHOP or R-CVP and did not demonstrate 
superiority in terms of ORRs, while PFS was not re-
ported70. Adverse events included more hypersensitiv-
ity reactions, vomiting and nausea, and infection rate 
was not reduced. Th ese results sparked doubt on the 
role of bendamustine in fi rst line treatment and on-
going controversy whether B-R regimen should re-
place current standard regimens in FL and has not 
been granted universal approval for this indication. 
Nevertheless, ever more patients are being treated with 
B-R regimen questioning appropriateness of which 
has led to the question whether subsequent rituximab 
maintenance still plays a role in this setting. Rituximab 
maintenance following B-R induction is being evalu-
ated in the ongoing MAINTAIN study67. Preliminary 
results have shown feasibility of the approach, but we 
will have to wait if diff erence in PFS will be achieved 
between maintenance arms and observation arm.
Th e greatest challenge to rituximab maintenance 
poses the relatively new introduction of B-cell receptor 
(BCR) pathway inhibitors into the fi eld of NHLs68. 
Th ese agents have rapidly changed therapy approach 
as tyrosine kinase inhibitors. In indolent NHLs, the 
most important member of the class is currently idelal-
isib, a phophatidylinositol-3 kinase δ inhibitor. Based 
on the preliminary data on its activity in indolent 
NHLs, a randomized, clinical trial was performed on 
125 heavily pretreated patients with indolent NHLs69. 
Idelalisib has shown satisfactory activity with ORR of 
57% and median duration of response of 12.5 months, 
which was granted by FDA approval for refractory and 
relapsed indolent NHLs70. Although this agent alone 
cannot produce durable CRs, its low toxicity in re-
lapsed setting and new mechanism of action make ide-
lalisib a preferable target for various combinations. 
Recently, a great setback has occurred with idelalisib71. 
Th e interim safety analysis of trials exploring idelalisib 
in combinations with cytotoxic drugs has shown infe-
rior OS due to toxicity profi le (Pneumocystis jirovecii 
infections, cytomegalovirus reactivation, high rates of 
transaminitis and pneumonitis), which led to suspen-
sion of RCTs in fi rst line setting. Other BCR pathway 
inhibitors for indolent NHLs, such as venetoclax, are 
explored in phase I/II trials and proper introduction of 
these agents in real time clinical practice will not occur 
soon.
Conclusion
Th e existing data indicate that rituximab mainte-
nance in advanced high tumor FL is effi  cient for:
1. prolonged PFS
2. prolonged OS in relapsed FL
3. optimization of response
4. low toxicity profi le
5. adequate cost-benefi t profi le
6. no negative interference with QoL
Recommended treatment algorithms are presented 
in Figures 1 and 2. Rituximab maintenance may be 
used in fi rst and second line treatment of advanced 
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high tumor burden FL according to the national guide-
lines for lymphoma diagnosis and treatment19. Despite 
current controversies surrounding this strategy, current 
data suggest that rituximab maintenance may and need 
to be employed in modern treatment of FL.
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Sažetak
ODRŽAVANJE RITUKSIMABOM U UZNAPREDOVALOM FOLIKULARNOM LIMFOMU: 
KONTROVERZIJE
V. Milunović, M. Bogeljić Patekar, K. Mišura Jakubac, I. Mandac Rogulj, D. Radić-Krišto, 
A. Planinc-Peraica i S. Ostojić Kolonić
Rituksimab je kimerično antiCD20 protutijelo koje se koristi u liječenju CD20 pozitivnih ne-Hodgkinovih limfoma te 
je promijenilo paradigmu liječenja ovih hematoloških neoplazma u prošlom desetljeću. Glavni cilj ovoga preglednog rada je 
predstaviti njegovu primjenu u folikularnom limfomu (FL) s naglaskom na terapiju održavanja. Ova strategija doprinijela je 
boljem preživljenju bez progresije bolesti u prvoj i drugoj liniji terapije, odnosno boljem ukupnom preživljenju u bolesnika s 
relapsom FL-a. No, usprkos dobrim rezultatima, održavanje rituksimabom je doprinijelo kontroverzi u medicinskoj zajed-
nici. Navedene nedoumice potječu od nedostatka poboljšanja ukupnog preživljenja u prvoj liniji terapije, moguće toksičnosti 
do nepoznate uloge u eri novih lijekova za liječenje FL-a. Prema postojećim podacima zaključujemo da terapiju održavanja 
rituksimabom treba ponuditi bolesnicima s FL-om koji su odgovorili na prvu liniju terapije te bolesnicima s relapsom FL-a 
koji su odgovorili na reindukciju, a nisu kandidati za liječenje autolognom transplantacijom matičnih stanica.
Ključne riječi: Rituksimab; Limfom, ne-Hodgkinov – terapija; Limfom, folikularni; Terapija održavanja; Ishod liječenja
